2024
Use of Muscle Relaxants After Surgery in Traditional Medicare Part D Enrollees
Bongiovanni T, Gan S, Finlayson E, Ross J, Harrison J, Boscardin J, Steinman M. Use of Muscle Relaxants After Surgery in Traditional Medicare Part D Enrollees. Drugs & Aging 2024, 41: 615-622. PMID: 38980644, PMCID: PMC11249446, DOI: 10.1007/s40266-024-01124-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overDrug PrescriptionsFemaleHumansMaleMedicare Part DPain, PostoperativePractice Patterns, Physicians'Retrospective StudiesUnited StatesConceptsMuscle relaxant prescriptionsOlder adultsSpine proceduresPain controlMuscle relaxationRisk of prolonged useProlonged useMedication-related problemsDecreased opioid useRates of prescribingMuscle relaxant useResultsThe study cohortPostoperative pain managementPrescribed to patientsYears of agePostoperative prescribingStudy DesignUsingNonopioid medicationsOpioid useOpioid prescribingMedicare Part DPostoperative periodMedicare Part D enrolleesRetrospective analysisPain management
2023
Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older Adults
Bongiovanni T, Gan S, Finlayson E, Ross J, Harrison J, Boscardin W, Steinman M. Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older Adults. JAMA Network Open 2023, 6: e2318626. PMID: 37326989, PMCID: PMC10276300, DOI: 10.1001/jamanetworkopen.2023.18626.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalgesics, OpioidCross-Sectional StudiesDrug PrescriptionsFemaleHumansMaleMedicarePainPractice Patterns, Physicians'Retrospective StudiesUnited StatesConceptsPostoperative periodCross-sectional studyGabapentinoid prescribingSurgical proceduresConcomitant prescribingGabapentinoid prescriptionOlder adultsPostoperative prescribingProcedure typeSerial cross-sectional studyPatients 66 yearsUse of gabapentinoidsProportion of patientsTotal study cohortAdverse drug eventsCommon surgical procedureConcurrent prescribingMultimodal painPostoperative opioidsOpioid prescribingOpioid usePain SocietyStudy cohortMean ageDrug eventsLongitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014
Sankar A, Everhart A, Jena A, Jeffery M, Ross J, Shah N, Karaca-Mandic P. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. The Joint Commission Journal On Quality And Patient Safety 2023, 49: 458-466. PMID: 37380503, DOI: 10.1016/j.jcjq.2023.05.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansHypogonadismMaleMedicareOff-Label UsePractice Patterns, Physicians'TestosteroneUnited StatesUnited States Food and Drug AdministrationConceptsCoronary artery diseaseFDA safety communicationPhysician characteristicsLabel prescribingCare physiciansTestosterone prescribingService administrative claims dataNon-primary care physiciansCertain physician characteristicsDrug Administration (FDA) safety communicationPrimary care physiciansAdministrative claims dataCase mix indexTestosterone therapyArtery diseaseTestosterone prescriptionsPrescribing levelsMean agePrescription trendsTeaching hospitalClaims dataPrescription levelsMedicare feePrescribingUS Food
2022
Prolonged use of newly prescribed gabapentin after surgery
Bongiovanni T, Gan S, Finlayson E, Ross J, Harrison JD, Boscardin J, Steinman MA. Prolonged use of newly prescribed gabapentin after surgery. Journal Of The American Geriatrics Society 2022, 70: 3560-3569. PMID: 36000860, PMCID: PMC9771946, DOI: 10.1111/jgs.18005.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalgesics, OpioidFemaleGabapentinHumansMaleMedicareOpioid-Related DisordersPain, PostoperativePractice Patterns, Physicians'Retrospective StudiesUnited StatesConceptsUse of gabapentinProlonged useOpioid useNon-opioid pain medicationsHigher Charlson comorbidity scoreOlder adultsPostoperative opioid prescribingProlonged opioid useCharlson comorbidity scoreLength of stayAdverse drug eventsTotal hip replacementLogistic regression modelsGabapentinoid useMore comorbiditiesComorbidity scoreGabapentin useOpioid prescribingOpioid prescriptionsDischarge dispositionEmergency surgeryPain medicationPatient characteristicsPrimary outcomeMultivariable analysisAssociation Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
Duarte-García A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS, Ross JS, Matteson EL, Shah ND. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings 2022, 97: 250-260. PMID: 35120693, PMCID: PMC9013005, DOI: 10.1016/j.mayocp.2021.08.026.Peer-Reviewed Original ResearchMeSH KeywordsCross-Sectional StudiesDrug CostsDrug IndustryHumansMedicare Part DPractice Patterns, Physicians'Prescription DrugsRetrospective StudiesRheumatologyUnited States
2021
Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration
Sankar A, Swanson KM, Zhou J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration. JAMA Network Open 2021, 4: e2136662. PMID: 34851398, PMCID: PMC8637256, DOI: 10.1001/jamanetworkopen.2021.36662.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmbulatory CareAnti-Bacterial AgentsBronchitisCross-Sectional StudiesDrug LabelingDrug PrescriptionsFemaleFluoroquinolonesHealth Plan ImplementationHumansInterrupted Time Series AnalysisMaleMedicareMiddle AgedPractice Patterns, Physicians'SinusitisUnited StatesUnited States Food and Drug AdministrationUrinary Tract InfectionsConceptsPrescribing of fluoroquinolonesCross-sectional studyBlack box warningFDA warningCare physiciansPrescribing levelsBox warningMAIN OUTCOMEUS FoodDrug AdministrationMedicare administrative claims dataUncomplicated urinary tract infectionsNon-primary care physiciansAcute care visitsUrinary tract infectionFDA black box warningPrimary care physiciansAdministrative claims dataCase mix indexFluoroquinolone prescriptionsPrescribing trendsCare visitsPrescribing ratesTract infectionsOutpatient visitsClinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
Wheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. JAMA Network Open 2021, 4: e2137288. PMID: 34870678, PMCID: PMC8649845, DOI: 10.1001/jamanetworkopen.2021.37288.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAtrial FibrillationFactor Xa InhibitorsHumansMedicarePractice Patterns, Physicians'Retrospective StudiesTime FactorsUnited StatesWarfarinConceptsDOAC useAnticoagulant prescriptionOral anticoagulantsUS cliniciansMedicare beneficiariesNational clinical practice guidelinesElevated bleeding riskOral anticoagulant prescriptionsRetrospective cohort studyDirect oral anticoagulantsClinical practice guidelinesUS Medicare beneficiariesInternal medicine physiciansNumber of cliniciansAnticoagulant prescribingDOAC prescriptionsUnique cliniciansBleeding riskCohort studyAnticoagulant strategiesPrescription claimsPractice guidelinesMAIN OUTCOMEMost indicationsMedicare populationUptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrology 2021, 22: 284. PMID: 34419007, PMCID: PMC8379779, DOI: 10.1186/s12882-021-02491-y.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsChronic kidney diseaseEpoetin alfaDarbepoetin alfaTREAT trialTypes of ESAsNew clinical evidencePrimary care physiciansMedicare AdvantageUptake of evidenceCare physiciansAnemia treatmentClinical evidenceKidney diseasePhysician genderMedicare feeUnsafe treatmentSegmented regression approachStudy periodPhysiciansService populationConsistent changesAlfaHigher useTreatmentU.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016
Wallach JD, Rhee TG, Edelman EJ, Shah ND, O’Malley S, Ross JS. U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016. Journal Of General Internal Medicine 2021, 37: 495-498. PMID: 33674920, PMCID: PMC8811103, DOI: 10.1007/s11606-021-06668-x.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAmbulatory CareHealth Care SurveysHumansOff-Label UseOutpatientsPractice Patterns, Physicians'United StatesPhysician variation in the de‐adoption of ineffective statin and fibrate therapy
Everhart A, Desai NR, Dowd B, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Smith LB, Karaca‐Mandic P. Physician variation in the de‐adoption of ineffective statin and fibrate therapy. Health Services Research 2021, 56: 919-931. PMID: 33569804, PMCID: PMC8522575, DOI: 10.1111/1475-6773.13630.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes Mellitus, Type 2Drug Therapy, CombinationDrug UtilizationFemaleFibric AcidsGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsLongitudinal StudiesMaleMedicare Part CMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Risk FactorsUnited StatesConceptsMedicare Advantage patientsType 2 diabetic patientsACCORD lipid trialFibrate useAdvantage patientsCommercial patientsPhysician characteristicsLIPID trialFibrate therapyDiabetic patientsPhysician variationDiabetes careType 2 diabetes diagnosisContinuous insurance enrollmentPatient diabetes carePhysician random effectsGlucose-lowering drugsElectronic health record dataHealth record dataReal-world data assetConcurrent statinCardiovascular eventsStatin usersClinical evidenceManagement visits
2020
Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions
Feder SL, Canavan ME, Wang S, Kent EE, Kapo J, Presley CJ, Ross J, Davidoff AJ. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. Journal Of Palliative Medicine 2020, 24: 195-204. PMID: 32673139, PMCID: PMC7840305, DOI: 10.1089/jpm.2020.0193.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalgesics, OpioidHumansMedicare Part CMedicare Part DPainPractice Patterns, Physicians'United StatesConceptsCardiopulmonary conditionsOpioid useMedicare Part D prescription claimsPatterns of opioidSevere pain interferenceUse of opioidsInitiation of opioidsMedicare Advantage beneficiariesNon-Hispanic blacksSelf-reported historyNon-Hispanic whitesOpioid prescribingSevere painNoncancer conditionsPain assessmentPain interferencePrescription claimsAdjusted proportionObservational studyPainPatientsOpioidsLogistic regressionOne-yearCancerPatient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm
Smith LB, Desai NR, Dowd B, Everhart A, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm. International Journal Of Health Economics And Management 2020, 20: 299-317. PMID: 32350680, PMCID: PMC7725279, DOI: 10.1007/s10754-020-09282-2.Peer-Reviewed Original ResearchConceptsPermanent atrial fibrillationType 2 diabetesAtrial fibrillationPermanent atrial fibrillation patientsProvider-level factorsAtrial fibrillation patientsEffective new therapiesPrimary care providersUse of medicationsProvider-level characteristicsUtilization of treatmentHigh-quality health careDronedarone useInterrupted time-series regression modelsFibrillation patientsMedication useDiabetes patientsProvider characteristicsCare providersMedicare feeNew therapiesService claimsFemale providersPatientsMedications
2019
Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
McCoy R, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah N. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technology & Therapeutics 2019, 21: 702-712. PMID: 31418588, PMCID: PMC7207017, DOI: 10.1089/dia.2019.0213.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGlucose-lowering medicationsHeart failureKidney diseaseMyocardial infarctionHigh-quality diabetes careMedicare Advantage insurancePrevalent adverse effectsRenal protective benefitsTreatment-risk paradoxNationwide cohort studyCotransporter 2 inhibitorsGlucose-lowering therapyPrior myocardial infarctionGlucose lowering medicationsChronic diabetes complicationsMultivariable logistic regressionNon-black patientsType 2 diabetesDiabetes type 1Insurance-related factorsCommercial health insuranceAppropriateness of usePrior hypoglycemiaSGLT2i initiationEvolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment
DuBose‐Briski V, Yao X, Dunlay SM, Dhruva SS, Ross JS, Shah ND, Noseworthy PA. Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment. Journal Of The American Heart Association 2019, 8: e012065. PMID: 31566106, PMCID: PMC6806052, DOI: 10.1161/jaha.119.012065.Peer-Reviewed Original ResearchMeSH KeywordsAmerican Heart AssociationCardiologistsCardiologyCardiovascular DiseasesEvidence-Based MedicineHumansPractice Guidelines as TopicPractice Patterns, Physicians'Time FactorsUnited StatesConceptsValvular heart diseaseClinical practice guidelinesAmerican Heart AssociationLevel of evidenceAmerican CollegeLOE BHeart failureHeart AssociationHeart diseasePractice guidelinesCardiology/American Heart Association (ACC/AHA) guideline recommendationsCardiology/American Heart Association guidelinesCardiology/American Heart AssociationMedian proportionCardiology clinical practice guidelinesAmerican Heart Association guidelinesHeart Association guidelinesClass of recommendationLOE AGuideline recommendationsResults ThirtyAssociation guidelinesMedian numberStable ischemiaLevel IRates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016
Jeffery MM, Hooten WM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016. JAMA Network Open 2019, 2: e198325. PMID: 31373650, PMCID: PMC6681551, DOI: 10.1001/jamanetworkopen.2019.8325.Peer-Reviewed Original ResearchConceptsLong-term opioid useOpioid usePrevention guidelinesMA groupDisease controlCoprescription of opioidsRetrospective cohort studyUS national databaseInsurance groupsMedicare AdvantageSickle cell diseaseGuideline releasePrescription daysPrescribed opioidsBenzodiazepine prescriptionsCohort studyMedian agePharmacy claimsChronic painCell diseaseCoprescriptionMAIN OUTCOMESame clinicianClaims dataHospice careAssociation of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids
Fleischman W, Agrawal S, Gross CP, Ross JS. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids. Journal Of General Internal Medicine 2019, 34: 1074-1076. PMID: 31011967, PMCID: PMC6614247, DOI: 10.1007/s11606-019-04897-9.Peer-Reviewed Original ResearchAnalgesics, OpioidCross-Sectional StudiesDrug IndustryHumansMedicare Part DPractice Patterns, Physicians'United StatesKept in the dark: Scotland rejects “sunshine” legislation
Ross JS. Kept in the dark: Scotland rejects “sunshine” legislation. The BMJ 2019, 364: l1379. PMID: 30926587, DOI: 10.1136/bmj.l1379.Commentaries, Editorials and LettersConflict of InterestDisclosureDrug IndustryHealth Services AccessibilityHumansPhysiciansPolicyPractice Patterns, Physicians'Prescription DrugsScotlandU.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015
Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. Preventive Medicine 2019, 123: 123-129. PMID: 30894321, PMCID: PMC6534435, DOI: 10.1016/j.ypmed.2019.03.022.Peer-Reviewed Original ResearchConceptsPain medication prescriptionsAmbulatory Medical Care SurveyOutpatient visitsED visitsMedication prescriptionsPain medicationCare SurveyNational Hospital Ambulatory Medical Care SurveyNational Ambulatory Medical Care SurveyOffice-based outpatient visitsNon-opioid alternativesCurrent opioid crisisEmergency department settingOpioid-related deathsPublic health interventionsRates of fentanylGeneral opioidOpioid prescribingFentanyl useED settingEmergency departmentOutpatient settingFentanyl productsDepartment settingOpioid products
2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellClinical Trials as TopicFemaleFollow-Up StudiesHumansKidney NeoplasmsLung NeoplasmsMaleMiddle AgedNivolumabPractice Patterns, Physicians'PrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesConceptsNon-small cell lung cancerPivotal clinical trialsRenal cell carcinomaCell death 1 proteinEligible patientsImmune checkpoint inhibitorsDeath 1 proteinClinical trialsClinical practiceFDA approvalAgent treatmentCheckpoint inhibitorsAnti-PD-1 agentsFlatiron Health networkRetrospective cohort studyAge of patientsCell lung cancerClinical trial participantsCohort studyPatient ageYounger patientsMore patientsSuch patientsTrial evidenceCell carcinomaPatterns and predictors of off-label prescription of psychiatric drugs
Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLOS ONE 2018, 13: e0198363. PMID: 30024873, PMCID: PMC6053129, DOI: 10.1371/journal.pone.0198363.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBipolar DisorderCitalopramCross-Sectional StudiesDrug PrescriptionsFemaleHumansInappropriate PrescribingInsurance, Major MedicalMaleMiddle AgedOff-Label UseOffice VisitsOutpatientsPractice Patterns, Physicians'Retrospective StudiesSleep Initiation and Maintenance DisordersTrazodoneUnited StatesConceptsNational Ambulatory Medical Care SurveyLabel prescribingChronic care managementPsychiatric drugsOutpatient visitsLabel prescriptionsCare managementAmbulatory Medical Care SurveyCommon off-label usesAdult outpatient visitsMore chronic conditionsMain outcome measuresOff-label useCross-sectional studyOff-label usesTypes of cliniciansManic-depressive psychosisStrong scientific evidenceVisit diagnosesAdverse eventsOffice visitsCare SurveyLabel usePsychiatric medicationsChronic conditions